CRESCENT BIOPHARMA, INC.

Regulatory Filings • May 24, 2017

8-K 1 a17-14131_18k.htm 8-K

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*Washington, DC 20549*

*FORM 8-K*

*CURRENT REPORT*

*Pursuant to Section 13 or 15(d) of*

*The Securities Exchange Act of 1934*

Date of Report (Date of earliest event reported): May 23, 2017

*GlycoMimetics, Inc.*

(Exact name of registrant as specified in its charter)

Delaware	001-36177	06-1686563
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

*9708 Medical Center Drive*

*Rockville, MD 20850*

(Address of principal executive offices, including zip code)

*(240) 243-1201*

(Registrant’s telephone number, including area code)

*N/A*

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

SEQ.=1,FOLIO='',FILE='C:\JMS\105733\17-14131-1\task8446594\14131-1-ba.htm',USER='105733',CD='May 24 11:08 2017'

*Item 1.02 Termination of a Material Definitive Agreement*

On May 23, 2017, GlycoMimetics, Inc. (the “Company”) terminated its Sales Agreement (the “Sales Agreement”), dated March 1, 2016, with Cowen and Company, LLC (“Cowen”), pursuant to which the Company could from time to time sell shares of its common stock having an aggregate offering price of up to $40.0 million through Cowen as sales agent. Prior to termination, the Company sold an aggregate of 2,057,438 shares of its common stock pursuant to the Sales Agreement for gross proceeds of $11,941,950.

The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed by the Company on March 1, 2016 and is incorporated herein by reference.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\105733\17-14131-1\task8446594\14131-1-ba.htm',USER='105733',CD='May 24 11:08 2017'

*SIGNATURES*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GLYCOMIMETICS, INC.
By:	/s/ Brian M. Hahn
Date: May 24, 2017	Brian M. Hahn
	Chief Financial Officer

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\105733\17-14131-1\task8446594\14131-1-ba.htm',USER='105733',CD='May 24 11:08 2017'